TAM
VIVO

Tiverton Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Tiverton Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-180,000
Closed -$3.19M – 209
2016
Q4 		$3.19M Buy
+180,000
New +$3.16M 0.19% 136

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Tiverton Asset Management's VIVO Position: Q1 2017 in Review

Tiverton Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2017, closing a stake of 180,000 shares — an estimated $3.19M sold.

Tiverton Asset Management first reported a position in VIVO in Q4 2016 and held it in 1 quarter. The position peaked at $3.19M in Q4 2016. 165 funds tracked by Wall St. Rank hold VIVO as of Q1 2017.

  • Tiverton Asset Management reported no remaining Meridian Bioscience Inc position as of Q1 2017 after selling out during the quarter.
  • Tiverton Asset Management sold 180,000 Meridian Bioscience Inc shares in Q1 2017, an estimated $3.19M.
  • Tiverton Asset Management first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 1 quarter.
  • Tiverton Asset Management's Meridian Bioscience Inc position peaked at $3.19M in Q4 2016.
  • 165 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2017.

Based on Tiverton Asset Management's 13F filing for Q1 2017, filed 15 May 2017.